“Amyloidosis Treatment Market Report is set to have rapid growth due the Increased adoption of novel targeted therapies and transplantations, emergence of biologics, and rising geriatric population at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report
04 September 2019
Visiongain has launched a new pharma report Amyloidosis Treatment Market Forecast 2019-2029 : By Treatment (Stem Cell Transplant, Chemotherapy, Supportive Care, Surgery, Targeted Therapy), By Country, And Segment Forecasts.
The global Amyloidosis Treatment market is poised for rapid growth between 2019 and 2029. The increase in the adoption of new targeted therapies and transplants, the emergence of biological drugs and the increase in the geriatric population are some of the factors that will collectively drive the market.
Amyloidosis is one of the rare diseases that are caused by the amyloid substance that starts to accumulate in different organs. Amyloid is a type of abnormal protein produced by bone marrow that can be stored in any organ or tissue. Diseases can affect different organs in different people; there are various types of illness. An estimated 16,000 people in the United States suffer from amyloidosis, with around 3,000 to 4,000 new cases reported each year.
The treatment of amyloidosis is growing due to factors such as; emerging organic sector, a growing number of elderly people around the world, a growing use of new ways (such as transplants and targeted therapies), etc. Therefore, the market for the treatment of amyloidosis is expected to expand and have an enormous range during the forecast period. Targeted therapies and stem cell transplants are catching on in developed countries. However, most of the world's population does not have access to sufficient health infrastructure to ensure rapid diagnosis and treatment in low-income economies.
Leading companies featured in the report include Pfizer, Inc.; Ionis Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Ltd.; Johnson and Johnson Pvt. Ltd.; and Alnylam Pharmaceuticals, Inc.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.
02 March 2021
Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.
26 February 2021
The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.
22 February 2021
The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.